Hendershot Investments Inc. Trims Holdings in Pfizer Inc. (NYSE:PFE)

Hendershot Investments Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,111 shares of the biopharmaceutical company’s stock after selling 784 shares during the quarter. Hendershot Investments Inc.’s holdings in Pfizer were worth $640,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. D Orazio & Associates Inc. lifted its stake in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 391 shares in the last quarter. Kingsview Wealth Management LLC raised its holdings in Pfizer by 28.8% during the fourth quarter. Kingsview Wealth Management LLC now owns 159,281 shares of the biopharmaceutical company’s stock valued at $4,226,000 after acquiring an additional 35,652 shares during the period. Vest Financial LLC lifted its position in shares of Pfizer by 15.1% in the fourth quarter. Vest Financial LLC now owns 27,234 shares of the biopharmaceutical company’s stock valued at $723,000 after acquiring an additional 3,573 shares in the last quarter. BayBridge Capital Group LLC boosted its stake in shares of Pfizer by 2.0% in the fourth quarter. BayBridge Capital Group LLC now owns 39,329 shares of the biopharmaceutical company’s stock worth $1,043,000 after acquiring an additional 768 shares during the period. Finally, Quattro Financial Advisors LLC grew its position in shares of Pfizer by 6.6% during the fourth quarter. Quattro Financial Advisors LLC now owns 170,781 shares of the biopharmaceutical company’s stock worth $4,507,000 after purchasing an additional 10,517 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on PFE shares. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

NYSE:PFE opened at $25.76 on Friday. The firm has a market capitalization of $145.96 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $26.28 and a 200-day simple moving average of $27.74. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the firm earned $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.68%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.